Results 151 to 160 of about 8,545 (210)

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2. [PDF]

J Clin Invest
Esmaeili S, Owens K, de Leon UA, Standing JF, Lowe DM, Zhang S, Watson JA, Schilling WH, Wagoner J, Polyak SJ, Schiffer JT.   +10 more
europepmc   +1 more source

Tackling emerging viral diseases with epidemic potential [PDF]

Li, Pengfei
core  

Successful Treatment of Persistent and Relapsing COVID-19 with Ensitrelvir in a Patient with Obinutuzumab-Induced Long-Term B-Cell Depletion: A Case Report. [PDF]

Reports (MDPI)
Haino Y, Kenzaka T, Hayashi T, Yakushijin K.   +3 more
europepmc   +1 more source

Developing Synthetic Full-Length SARS-CoV-2 cDNAs and Reporter Viruses for High-Throughput Antiviral Drug Screening. [PDF]

Viruses
Rohamare M, Kaushik N, Khan JQ, Balouchi M, Lopez-Orozco J, Kozak R, Hobman TC, Falzarano D, Kumar A, Wilson JA.   +9 more
europepmc   +1 more source

Treatment Duration of Each Anti-COVID-19 Agent Used in a Tertiary Hospital in Japan. [PDF]

Cureus
Seki M, Enami K.
europepmc   +1 more source

Developing New Drugs for the COVID-19 Emergency: Anatomy of the U.S. Response. [PDF]

Pharmacotherapy
Moore TJ, Socal MP, Anderson G.
europepmc   +1 more source

Multi spectroscopic investigations with molecular docking and molecular dynamics simulation of the binding mechanism of molnupiravir to bovine serum albumin. [PDF]

BMC Chem
Mansour FR, Elhosary N, Elagamy SH, Barseem A, Kamal AH.   +4 more
europepmc   +1 more source

Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection. [PDF]

Pharmaceutics
Shen Y, Eades W, Dinh L, Yan B.
europepmc   +1 more source

A cost-effectiveness analysis of Molnupiravir and Paxlovid for outpatient treatment of COVID-19 in three African countries. [PDF]

J Public Health Afr
Edoka IP, Drake T, Baker P, Tajudeen R, Asfaw E, Guzman J, Ndembi N, Nonvignon J, Kaseya J.   +8 more
europepmc   +1 more source